Efficacy Conclusions

• Improved pulmonary hemodynamics: cardiac index, mean PAP, PVR and mean RAP(125 mg bid)
• Decreased risk of clinical worsening

With extended treatment:
• Clinical benefits maintained; no evidencefor tolerance

9047.01

Previous slide

Next slide

Back to first slide

View graphic version